GlassScriptPhysician profile
David J Buchanan
NPI 1639377120
$3,664.01
in general payments reported to CMS, 2019-2025
24 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $37.82 · 2021: $302 · 2022: $970 · 2023: $1,013 · 2024: $845 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,030.85 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $650.87 | 2022-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $366.43 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $187.98 | 2020-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $161.80 | 2022-2025 | |
| Amgen INC. | $150.18 | 2020-2025 | Repatha, Repatha |
| Heartflow, INC. | $143.14 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $133.80 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.55 | 2022-2024 | Jardiance |
| Tactile Systems Technology INC | $117.32 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Novo Nordisk INC | $109.68 | 2023-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $87.92 | 2022-2023 | Camzyos |
| Vifor Pharma, INC. | $73.40 | 2021-2022 | |
| Amarin Pharma, INC. | $53.58 | 2021 | |
| Shockwave Medical, INC | $49.36 | 2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.73 | 2022 | |
| Cvrx, INC. | $32.60 | 2023 | Barostim Neo System |
| Abiomed | $29.91 | 2024 | Impella |
| Ethicon US, LLC | $24.72 | 2019 | |
| Irhythm Technologies, INC. | $23.75 | 2024 | Zio Xt Patch, Zio Monitor |
| Lexicon Pharmaceuticals, INC. | $22.18 | 2023 | Inpefa |
| Pfizer INC. | $21.16 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.10 | 2023 | Arcalyst |
| United Therapeutics Corporation | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.